| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
83,754,000 |
| Market
Cap: |
685.95(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.54 - $21.08 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 11 |
| Insider 6 Months : 11 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
100,000 |
100,000 |
100,000 |
100,000 |
| Total Buy Value |
$713,346 |
$713,346 |
$713,346 |
$713,346 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
3 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
25,799 |
49,084 |
160,601 |
| Total Sell Value |
$0 |
$200,525 |
$388,115 |
$2,623,845 |
| Total People Sold |
0 |
3 |
7 |
9 |
| Total Sell Transactions |
0 |
3 |
10 |
17 |
| End Date |
2025-06-15 |
2025-03-14 |
2024-09-13 |
2023-09-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wilson Troy Edward |
President & CEO |
• • – |
2025-09-08 |
4 |
B |
$8.20 |
$410,145 |
D/D |
50,000 |
100,968 |
0.01 |
8% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2025-08-13 |
4 |
B |
$6.64 |
$89,623 |
D/D |
13,494 |
50,968 |
0.01 |
36% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2025-08-12 |
4 |
B |
$5.85 |
$213,578 |
D/D |
36,506 |
37,474 |
0.01 |
42% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2025-05-19 |
4 |
AS |
$6.28 |
$9,777 |
D/D |
(1,558) |
21,367 |
|
31% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2025-05-19 |
4 |
AS |
$5.96 |
$9,292 |
D/D |
(1,559) |
107,948 |
|
31% |
|
| Hasnain Faheem |
|
– • – |
2025-03-21 |
4 |
AS |
$8.00 |
$181,456 |
D/D |
(22,682) |
23,983 |
|
-23% |
|
| Hasnain Faheem |
|
– • – |
2025-03-21 |
4 |
OE |
$6.32 |
$143,350 |
D/D |
22,682 |
46,665 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2025-01-28 |
4 |
S |
$7.87 |
$14,303 |
D/D |
(1,817) |
21,367 |
|
13% |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2025-01-28 |
4 |
S |
$7.87 |
$12,461 |
D/D |
(1,583) |
59,667 |
|
13% |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2025-01-28 |
4 |
S |
$7.87 |
$39,068 |
D/D |
(4,963) |
88,253 |
|
13% |
|
| Burrows Francis |
Chief Scientific Officer |
• – – |
2025-01-28 |
4 |
S |
$7.87 |
$17,051 |
D/D |
(2,166) |
20,705 |
|
13% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2025-01-28 |
4 |
S |
$7.87 |
$57,315 |
D/D |
(7,281) |
107,948 |
|
13% |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2025-01-28 |
4 |
S |
$7.87 |
$38,958 |
D/D |
(4,949) |
88,193 |
|
13% |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2025-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,966 |
|
-34% |
|
| Burrows Francis |
Chief Scientific Officer |
• – – |
2025-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,871 |
|
-34% |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
46,250 |
93,216 |
|
- |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
46,250 |
115,229 |
|
- |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
46,250 |
61,250 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
93,142 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2024-11-18 |
4 |
S |
$16.03 |
$8,434 |
D/D |
(526) |
23,184 |
|
60% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2024-05-20 |
4 |
AS |
$22.15 |
$57,916 |
D/D |
(2,615) |
68,979 |
|
-12% |
|
| Dale Stephen |
Chief Medical Officer |
• – – |
2024-01-30 |
4 |
AS |
$21.55 |
$103,980 |
D/D |
(4,825) |
38,817 |
|
0% |
|
| Dale Stephen |
Chief Medical Officer |
• – – |
2024-01-29 |
4 |
AS |
$17.80 |
$127,416 |
D/D |
(7,158) |
43,642 |
|
17% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2024-01-29 |
4 |
S |
$17.80 |
$26,630 |
D/D |
(1,496) |
21,602 |
|
-17% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2024-01-29 |
4 |
S |
$17.80 |
$36,544 |
D/D |
(2,053) |
68,979 |
|
-17% |
|
121 Records found
|
|
Page 1 of 5 |
|
|
0.64 (7.2%) 
